Search clinical trials for: lenalidomide, bendamustine, rituximab

Total 4136 results

Seoul National University Hospital

Recruiting

GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Relapsed/Refractory Diffuse Large B Cell Lymphoma

Korea, Republic of
Celgene

Completed

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Myelodysplastic Syndromes

United States, Germany
University Hospital, Toulouse
Celgene; Intergroupe Francophone du Myelome

Completed

Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)

Myeloma

France, Belgium, Switzerland
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

Kidney Cancer

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
German CLL Study Group

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL (CLL2-BAAG)

Chronic Lymphoid Leukemia

Germany
Emory University
National Cancer Institute (NCI); Genentech, Inc.; National Institutes of Health...

Active, not recruiting

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | t(11;14) Positive

United States
Narendranath Epperla
Eli Lilly and Company

Not yet recruiting

Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
National Research Center for Hematology, Russia

Recruiting

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Primary CNS Lymphoma

Russian Federation
Sun Yat-sen University

Not yet recruiting

R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study

DLBCL
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Lymphoma

United States
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
Ruijin Hospital

Recruiting

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Follicular Lymphoma

China
Celgene

Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Multiple Myeloma

Ukraine, Russian Federation
King's College Hospital NHS Trust

Completed

The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

Myelodysplastic Syndromes

United Kingdom
National Cancer Institute (NCI)

Completed

CC-5013 in Treating Patients With Recurrent Glioma

Brain and Central Nervous System Tumors

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

A Phase II Study of CC-5013 in Myelofibrosis

Myelofibrosis

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

United States
University of Washington
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal...

United States
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Primary Central Nervous System Lymphoma (PCNSL) | Secondary Central Nervous System Lymphoma (SCNSL)

United States
Brian Hill
The Cleveland Clinic

Terminated

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Lymphoma | B Cell Lymphoma

United States
Fate Therapeutics

Recruiting

FT819 in Moderate to Severe Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
University Health Network, Toronto
Celgene Corporation

Completed

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin Disease
Yale University
Celgene Corporation

Terminated

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Celgene Corporation

Completed

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Radiculopathy

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Hodgkin Lymphoma

Australia, Israel, Korea, Republic of, Spain, Poland, Sweden, United Kingdom, Turkey, China, United States, Brazil, Germany, Belgium, France, Switzerland, Canada, Czechia, Chile
Charite University, Berlin, Germany
Wyeth is now a wholly owned subsidiary of Pfizer; Mundipharma K.K.

Withdrawn

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Mantle Cell Lymphoma

Germany
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

B-cell Non-Hodgkin's Lymphoma
The Lymphoma Academic Research Organisation
Centre Henri Becquerel

Completed

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (R2-CHOP2)

Follicular Lymphoma

France
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Samyang Biopharmaceuticals Corporation
Chungnam National University Hospital

Completed

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Healthy, Male
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Lymphoma Study Association

Completed

Lenalidomide and R-CHOP in B-cell Lymphoma (R2CHOP-1)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

France
Arbeitsgemeinschaft medikamentoese Tumortherapie
Roche Pharma AG; Celgene Corporation

Completed

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
Tessa Therapeutics
Bristol-Myers Squibb

Active, not recruiting

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ACTION)

Classical Hodgkin Lymphoma | Hodgkin Disease Recurrent | Hodgkin Disease Refractory

United States
PETHEMA Foundation
Janssen-Cilag Ltd.; Mundipharma Pharmaceuticals B.V.

Completed

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Spain
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
Novartis Pharmaceuticals
Bristol-Myers Squibb

Recruiting

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

United States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
Beijing Friendship Hospital

Recruiting

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

EBV Infection

China
German CLL Study Group
Celgene

Completed

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Chronic Lymphocytic Leukemia

Germany
Celgene Corporation

Terminated

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-002)

Complex Regional Pain Syndrome, Type I

United States
Telik

Completed

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 Positive

United States
Sandoz
Hexal AG

Completed

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)

Rheumatoid Arthritis

United States, Germany, Poland, Hungary
Parameswaran Hari

Completed

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Ruijin Hospital

Unknown

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

Diffuse Large B Cell Lymphoma

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Lymphoma

United States

Search clinical trials for: lenalidomide, bendamustine, rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations